首页
学术期刊
论文检测
AIGC检测
热点
更多
数据
CGP57698: A structurally simple, highly potent peptido-leukotriene (PLT) antagonist of the quinoline type
被引:0
|
作者
:
von Sprecher, A
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
von Sprecher, A
[
1
]
Gerspacher, M
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Gerspacher, M
[
1
]
Beck, A
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Beck, A
[
1
]
Anderson, GP
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Anderson, GP
[
1
]
Niederhauser, U
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Niederhauser, U
[
1
]
Subramanian, N
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Subramanian, N
[
1
]
Ball, HA
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Ball, HA
[
1
]
Gentsch, C
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Gentsch, C
[
1
]
Vassout, A
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Vassout, A
[
1
]
Felner, A
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Felner, A
[
1
]
Bittiger, H
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Bittiger, H
[
1
]
Hauser, K
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Hauser, K
[
1
]
Giese, K
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Giese, K
[
1
]
Kraetz, J
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Kraetz, J
[
1
]
Bray, MA
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Bray, MA
[
1
]
机构
:
[1]
Novartis Pharma AG, CH-4002 Basel, Switzerland
来源
:
RECENT ADVANCES IN PROSTAGLANDIN, THROMBOXANE, AND LEUKOTRIENE RESEARCH
|
1997年
/ 433卷
关键词
:
D O I
:
暂无
中图分类号
:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号
:
071010 ;
081704 ;
摘要
:
引用
收藏
页码:169 / 172
页数:4
相关论文
共 3 条
[1]
CGP-45715-A A LEUKOTRIENE-D4 ANALOG WITH POTENT PEPTIDO-LT ANTAGONIST ACTIVITY
BRAY, MA
论文数:
0
引用数:
0
h-index:
0
BRAY, MA
ANDERSON, WH
论文数:
0
引用数:
0
h-index:
0
ANDERSON, WH
SUBRAMANIAN, N
论文数:
0
引用数:
0
h-index:
0
SUBRAMANIAN, N
NIEDERHAUSER, U
论文数:
0
引用数:
0
h-index:
0
NIEDERHAUSER, U
KUHN, M
论文数:
0
引用数:
0
h-index:
0
KUHN, M
ERARD, M
论文数:
0
引用数:
0
h-index:
0
ERARD, M
VONSPRECHER, A
论文数:
0
引用数:
0
h-index:
0
VONSPRECHER, A
ADVANCES IN PROSTAGLANDIN THROMBOXANE AND LEUKOTRIENE RESEARCH,
1991,
21
: 503
-
507
[2]
LEUKOTRIENE (LT) ANALOGS - CGP-44044A, A HIGHLY POTENT PEPTIDOLEUKOTRIENE ANTAGONIST - STEREOCHEMICAL REQUIREMENTS
VONSPRECHER, A
论文数:
0
引用数:
0
h-index:
0
机构:
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
VONSPRECHER, A
SALLMANN, A
论文数:
0
引用数:
0
h-index:
0
机构:
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
SALLMANN, A
WIESTNER, HR
论文数:
0
引用数:
0
h-index:
0
机构:
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
WIESTNER, HR
ANDERSON, WH
论文数:
0
引用数:
0
h-index:
0
机构:
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
ANDERSON, WH
SUBRAMANIAN, N
论文数:
0
引用数:
0
h-index:
0
机构:
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
SUBRAMANIAN, N
BRAY, MA
论文数:
0
引用数:
0
h-index:
0
机构:
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
CIBA GEIGY AG, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND
BRAY, MA
EUROPEAN JOURNAL OF PHARMACOLOGY,
1990,
183
(02)
: 581
-
581
[3]
Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class
von Sprecher, A
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
von Sprecher, A
Gerspacher, M
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Gerspacher, M
Beck, A
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Beck, A
Kimmel, S
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Kimmel, S
Wiestner, H
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Wiestner, H
Anderson, GP
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Anderson, GP
Niederhauser, U
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Niederhauser, U
Subramanian, N
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Subramanian, N
Bray, MA
论文数:
0
引用数:
0
h-index:
0
机构:
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Novartis Pharma AG, Res Dept, CH-4002 Basel, Switzerland
Bray, MA
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,
1998,
8
(08)
: 965
-
970
←
1
→